SCHEMBL23014337

SCHEMBL23014337

CN(C)c1ccc(C(=O)CNC(=O)c2ccc(F)cc2F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
CBX7 O95931 1/20 0.44
CDYL2 Q8N8U2 1/20 0.44
CDYL Q9Y232 1/20 0.44
CDY1; CDY1B Q9Y6F8 1/20 0.44
KMT2A Q03164 2/20 0.43
APP P05067 2/20 0.42
MAPT P10636 4/20 0.41
ALDH1A1 P00352 3/20 0.41
POLB P06746 1/20 0.41
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
SNCA P37840 2/20 0.40
KDM4E B2RXH2 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23023272 0.88 NPC1 (0.47) CBX7CDYL2CDYLCDY1; CDY1BKMT2A
SCHEMBL23014117 0.84 MAPT (0.49) L3MBTL1KMT2AMAPTALDH1A1POLB
SCHEMBL23014292 0.84 KMT2A (0.56) L3MBTL1KMT2AAPPMAPTALDH1A1
SCHEMBL23014187 0.83 RAB9A (0.54) KMT2AMAPTALDH1A1CES2CES1
SCHEMBL23014377 0.82 ALDH1A1 (0.53) L3MBTL1KMT2AMAPTALDH1A1CES2
SCHEMBL23014128 0.80 ALDH1A1 (0.45) MAPTALDH1A1POLBCES2CES1
SCHEMBL23014470 0.75 HPGD (0.56) KMT2AMAPTALDH1A1KDM4ERAB9A
SCHEMBL15610344 0.74 CES2 (0.53) L3MBTL1CES2CES1SNCARAB9A
SCHEMBL23014396 0.74 ALDH1A1 (0.54) KMT2AMAPTALDH1A1POLBKDM4E
SCHEMBL12634168 0.74 ALDH1A1 (0.52) ALDH1A1POLBKDM4EGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021034087-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND 주식회사 셀젠텍 2021-02-25 WO claimed
US-20230150924-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND CELLGENTEK CO., LTD. (KR) 2023-05-18 US disclosed
EP-4019495-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND Cellgentek Co., Ltd (KR) 2022-06-29 EP disclosed
WO-2021034087-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND 주식회사 셀젠텍 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150924-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND KNTC1, MED1, LEF1 ACKR3 3069/4885L3MBTL1 3211/4885CBX7 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.